Computational profiling of natural compounds as promising inhibitors against the spike proteins of SARS-CoV-2 wild-type and the variants of concern, viral cell-entry process, and cytokine storm in COVID-19.
SARS-CoV-2 spike protein
cell-entry process
cytokine storm
molecular docking
molecular dynamics simulations
phytocompounds
variants of concern
Journal
Journal of cellular biochemistry
ISSN: 1097-4644
Titre abrégé: J Cell Biochem
Pays: United States
ID NLM: 8205768
Informations de publication
Date de publication:
05 2022
05 2022
Historique:
revised:
11
03
2022
received:
14
12
2021
accepted:
14
03
2022
pubmed:
29
3
2022
medline:
26
5
2022
entrez:
28
3
2022
Statut:
ppublish
Résumé
The continuous spread and evolution of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and the rapid surge in infection cases in the coronavirus disease 2019 (COVID-19) evoke a dire need for effective therapeutics. In this study, we explored the inhibitory potential of a library of 605 phytocompounds, selected from Indian medicinal plants with reported antiviral and anti-inflammatory activities, against the receptor-binding domain of spike proteins of the SARS-CoV-2 wild-type and the variants of concern, including variants B.1.1.7 (Alpha), B.1.351 (Beta), P.1 (Gamma), B.1.617.2 (Delta), and B.1.1.529 (Omicron). Our approach was based on extensive molecular docking, assessment of drug-likeness, and robust molecular dynamics simulations. We also identified promising inhibitory candidates against the host (human) proteins associated with SARS-CoV-2 spike activation and attachment, namely, ACE2 receptor, proteases TMPRSS2 and CTSL, and the endocytic regulator AAK1. In addition, we screened promising inhibitory compounds against the human proinflammatory cytokines- IL-6, IL-1β, TNF-α, and IFN-γ, that are associated with the adverse cytokine storm in COVID-19 patients. Our analysis returned an encouraging list of promising inhibitory candidates that includes: abietatriene against the spike proteins of the SARS-CoV-2 wild-type and the variants of concern; taraxerol against the human ACE2, CTSL and TNF-α; β-amyrin against the human TMPRSS2; cynaroside against the human AAK1 and IL-1β; and friedelin against the human IL-6 and IFN-γ. Our findings provide substantial evidence for the inhibitory potential of these compounds and encourage further in vitro and in vivo studies to validate their use as safe and effective therapeutics against COVID-19.
Substances chimiques
Interleukin-6
0
Spike Glycoprotein, Coronavirus
0
Tumor Necrosis Factor-alpha
0
spike protein, SARS-CoV-2
0
Angiotensin-Converting Enzyme 2
EC 3.4.17.23
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
964-986Informations de copyright
© 2022 Wiley Periodicals LLC.
Références
Lu R, Zhao X, Li J, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 2020;395(10224):565-574. doi:10.1016/S0140-6736(20)30251-8
Gordon DE, Jang GM, Bouhaddou M, et al. A SARS-CoV-2 protein interaction map reveals targets for drug repurposing. Nature. 2020;583(7816):459-468. doi:10.1038/s41586-020-2286-9
Lan J, Ge J, Yu J, et al. Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor. Nature. 2020;581(7807):215-220. doi:10.1038/s41586-020-2180-5
Yadav UC. Vaccines and drugs under clinical trials for prevention and treatment of COVID-19. Virusdisease. 2021;32:13-19. doi:10.1007/s13337-020-00650-7
Wang R, Chen J, Gao K, Wei GW. Vaccine-escape and fast-growing mutations in the United Kingdom, the United States, Singapore, Spain, India, and other COVID-19-devastated countries. Genomics. 2021;113(4):2158-2170. doi:10.1016/j.ygeno.2021.05.006
Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020;181(2):271-280. doi:10.1016/j.cell.2020.02.052
Zhao MM, Yang WL, Yang FY, et al. Cathepsin L plays a key role in SARS-CoV-2 infection in humans and humanized mice and is a promising target for new drug development. Signal Transduct Target Ther. 2021;6:134. doi:10.1038/s41392-021-00558-8
Stebbing J, Phelan A, Griffin I, et al. COVID-19: combining antiviral and anti-inflammatory treatments. Lancet Infect Dis. 2020;20(4):400-402. doi:10.1016/S1473-3099(20)30132-8
Del Valle DM, Kim-Schulze S, Huang HH, et al. An inflammatory cytokine signature predicts COVID-19 severity and survival. Nature Med. 2020;26(10):1636-1643. doi:10.1038/s41591-020-1051-9
Ragab D, Salah Eldin H, Taeimah M, Khattab R, Salem R. The COVID-19 cytokine storm; what we know so far. Front Immunol. 2020;11:1446. doi:10.3389/fimmu.2020.01446
Singh RS, Singh A, Kaur H, et al. Promising traditional Indian medicinal plants for the management of novel Coronavirus disease: a systematic review. Phytother Res. 2021;35:4456-4484. doi:10.1002/ptr.7150
Vellingiri B, Jayaramayya K, Iyer M, et al. COVID-19: a promising cure for the global panic. Sci Total Environ. 2020;725:138277. doi:10.1016/j.scitotenv.2020.138277
O'Boyle NM, Banck M, James CA, Morley C, Vandermeersch T, Hutchison GR. Open Babel: an open chemical toolbox. J Cheminf. 2011;3:33. doi:10.1186/1758-2946-3-33
Schüttelkopf AW, Van Aalten DM. PRODRG: a tool for high-throughput crystallography of protein-ligand complexes. Acta Crystallogr D. 2004;60(8):1355-1363. doi:10.1107/S0907444904011679
Dejnirattisai W, Zhou D, Supasa P, et al. Antibody evasion by the P.1 strain of SARS-CoV-2. Cell. 2021;184(11):2939-2954. doi:10.1016/j.cell.2021.03.055
Fraser BJ, Beldar S, Seitova A, et al. Structure, activity and inhibition of human TMPRSS2, a protease implicated in SARS-CoV-2 activation. bioRxiv. 2021. doi:10.1101/2021.06.23.449282
Giroud M, Dietzel U, Anselm L, et al. Repurposing a library of human cathepsin L ligands: identification of macrocyclic lactams as potent rhodesain and trypanosoma brucei inhibitors. J Med Chem. 2018;61(8):3350-3369. doi:10.1021/acs.jmedchem.7b01869
Sorrell FJ, Szklarz M, Azeez KRA, Elkins JM, Knapp S. Family-wide structural analysis of human numb-associated protein kinases. Structure. 2016;24(3):401-411. doi:10.1016/j.str.2015.12.015
Somers W, Stahl M, Seehra JS. 1.9 Å crystal structure of interleukin 6: implications for a novel mode of receptor dimerization and signaling. EMBO J. 1997;16(5):989-997. doi:10.1093/emboj/16.5.989
Kuo WC, Lee CC, Chang YW, et al. Structure-based development of human interleukin-1β-specific antibody that simultaneously inhibits binding to both IL-1RI and IL-1RAcP. J Mol Biol. 2021;433(4):166766. doi:10.1016/j.jmb.2020.166766
He MM, Smith AS, Oslob JD, et al. Small-molecule inhibition of TNF-alpha. Science. 2005;310(5750):1022-1025. doi:10.1126/science.1116304
Mendoza JL, Escalante NK, Jude KM, et al. Structure of the IFNγ receptor complex guides design of biased agonists. Nature. 2019;567(7746):56-60. doi:10.1038/s41586-019-0988-7
Harvey WT, Carabelli AM, Jackson B, et al. SARS-CoV-2 variants, spike mutations and immune escape. Nat Rev Microbiol. 2021;19(7):409-424. doi:10.1038/s41579-021-00573-0
Tao K, Tzou PL, Nouhin J, et al. The biological and clinical significance of emerging SARS-CoV-2 variants. Nat Rev Genet. 2021;22:757-773. doi:10.1038/s41576-021-00408-x
Trott O, Olson AJ. AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J Comput Chem. 2010;31(2):455-461. doi:10.1002/jcc.21334
Kar P, Kumar V, Vellingiri B, et al. Anisotine and amarogentin as promising inhibitory candidates against SARS-CoV-2 proteins: a computational investigation. J Biomol Struct Dyn. 2020;11:1-11. doi:10.1080/07391102.2020.1860133
Wang Q, Zhang Y, Wu L, et al. Structural and functional basis of SARS-CoV-2 entry by using human ACE2. Cell. 2020;181(4):894-904. doi:10.1016/j.cell.2020.03.045
Salentin S, Schreiber S, Haupt VJ, Adasme MF, Schroeder M. PLIP: fully automated protein-ligand interaction profiler. Nucleic Acids Res. 2015;43(W1):W443-W447. doi:10.1093/nar/gkv315
Daina A, Michielin O, Zoete V. SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Sci Rep. 2017;7:42717. doi:10.1038/srep42717
Pires DE, Blundell TL, Ascher DB. pkCSM: predicting small-molecule pharmacokinetic and toxicity properties using graph-based signatures. J Med Chem. 2015;58(9):4066-4072. doi:10.1021/acs.jmedchem.5b00104
Lagorce D, Bouslama L, Becot J, Miteva MA, Villoutreix BO. FAF-Drugs4: free ADME-tox filtering computations for chemical biology and early stages drug discovery. Bioinformatics. 2017;33(22):3658-3660. doi:10.1093/bioinformatics/btx491
Banerjee P, Eckert AO, Schrey AK, Preissner R. ProTox-II: a webserver for the prediction of toxicity of chemicals. Nucleic Acids Res. 2018;46(W1):W257-W263. doi:10.1093/nar/gky318
Cheng F, Li W, Zhou Y, et al. admetSAR: a comprehensive source and free tool for assessment of chemical ADMET properties. J Chem Inf Model. 2012;52:3099-3105. doi:10.1021/ci300367a
Schyman P, Liu R, Desai V, Wallqvist A. vNN web server for ADMET predictions. Front Pharmacol. 2017;8:889. doi:10.3389/fphar.2017.00889
Abraham MJ, Murtola T, Schulz R, et al. GROMACS: high performance molecular simulations through multi-level parallelism from laptops to supercomputers. SoftwareX. 2015;1:19-25. doi:10.1016/j.softx.2015.06.001
Yan R, Zhang Y, Li Y, Xia L, Guo Y, Zhou Q. Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2. Science. 2020;367(6485):1444-1448. doi:10.1126/science.abb2762
Zhu X, Mannar D, Srivastava SS, et al. Cryo-electron microscopy structures of the N501Y SARS-CoV-2 spike protein in complex with ACE2 and 2 potent neutralizing antibodies. PLoS Biol. 2021;19(4):e3001237. doi:10.1371/journal.pbio.3001237
Hatmal MMM, Alshaer W, Al-Hatamleh MA, et al. Comprehensive structural and molecular comparison of spike proteins of SARS-CoV-2, SARS-CoV and MERS-CoV, and their interactions with ACE2. Cells. 2020;9(12):2638. doi:10.3390/cells9122638
Huo J, Le Bas A, Ruza RR, et al. Neutralizing nanobodies bind SARS-CoV-2 spike RBD and block interaction with ACE2. Nat Struct Mol Biol. 2020;27(9):846-854. doi:10.1038/s41594-020-0469-6
Li Q, Wu J, Nie J, et al. The impact of mutations in SARS-CoV-2 spike on viral infectivity and antigenicity. Cell. 2020;182(5):1284-1294. doi:10.1016/j.cell.2020.07.012
Liu Z, VanBlargan LA, Bloyet LM, et al. Identification of SARS-CoV-2 spike mutations that attenuate monoclonal and serum antibody neutralization. Cell Host Microbe. 2021;29(3):477-488. doi:10.1016/j.chom.2021.01.014
Callaway E. Heavily mutated Omicron variant puts scientists on alert. Nature. 2021;600(7887):21. doi:10.1038/d41586-021-03552-w
Lipinski CA. Lead-and drug-like compounds: the rule-of-five revolution. Drug Discov Today Technol. 2004;1(4):337-341. doi:10.1016/j.ddtec.2004.11.007
Rani PR, Imran M, Lakshmi JV, et al. Symptomatic reinfection of SARS-CoV-2 with spike protein variant N440K associated with immune escape. J Med Virol. 2021;93:4163-4165. doi:10.1002/jmv.26997
Ohtsu H, Tanaka R, In Y, Matsunaga S, Tokuda H, Nishino H. Abietane diterpenoids from the cones of Larix kaempferi and their inhibitory effects on Epstein-Barr virus activation. Planta Med. 2001;67(1):55-60. doi:10.1055/s-2001-10873
Yu MS, Lee J, Lee JM, et al. Identification of myricetin and scutellarein as novel chemical inhibitors of the SARS coronavirus helicase, nsP13. Bioorg Med Chem Lett. 2012;22(12):4049-4054. doi:10.1016/j.bmcl.2012.04.081
Okoye NN, Ajaghaku DL, Okeke HN, Ilodigwe EE, Nworu CS, Okoye FBC. beta-Amyrin and alpha-amyrin acetate isolated from the stem bark of Alstonia boonei display profound anti-inflammatory activity. Pharm Biol. 2014;52(11):1478-1486. doi:10.3109/13880209.2014.898078
Guo H, Zheng J, Huang G, et al. Xuebijing injection in the treatment of COVID-19: a retrospective case-control study. Ann Palliat Med. 2020;9(5):3235-3248. doi:10.21037/apm-20-1478
Antonisamy P, Duraipandiyan V, Ignacimuthu S. Anti-inflammatory, analgesic and antipyretic effects of friedelin isolated from Azima tetracantha Lam. in mouse and rat models. J Pharm Pharmacol. 2011;63(8):1070-1077. doi:10.1111/j.2042-7158.2011.01300.x
Szekalska M, Sosnowska K, Tomczykowa M, Winnicka K, Kasacka I, Tomczyk M. In vivo anti-inflammatory and anti-allergic activities of cynaroside evaluated by using hydrogel formulations. Biomed Pharmacother. 2020;121:109681. doi:10.1016/j.biopha.2019.109681
Karki R, Sharma BR, Tuladhar S, et al. Synergism of TNF-α and IFN-γ triggers inflammatory cell death, tissue damage, and mortality in SARS-CoV-2 infection and cytokine shock syndromes. Cell. 2021;184:149-168. doi:10.1016/j.cell.2020.11.025
Yao X, Li G, Bai Q, Xu H, Lü C. Taraxerol inhibits LPS-induced inflammatory responses through suppression of TAK1 and Akt activation. Int Immunopharmacol. 2013;15(2):316-324. doi:10.1016/j.intimp.2012.12.032
Bickerton GR, Paolini GV, Besnard J, Muresan S, Hopkins AL. Quantifying the chemical beauty of drugs. Nat Chem. 2012;4(2):90-98. doi:10.1038/nchem.1243